BioXpedia A/S and BioSkryb Genomics Announce European Partnership to Provide Groundbreaking, Single-Cell, Multiomic Analysis for Novel Target Identification and Therapeutic Development
This new partnership brings high-resolution, single-cell whole genome and whole transcriptome analysis to Europe. This partnership will enable novel insights and deep cellular characterization required in the evaluation, creation, and validation of new generation biologics and therapeutics in targeted disease management.
GelSight Mini enables an enhanced AI-enabled tactile experience for users in just five minutes out of the box.
ImmunoScape Raises $14M to Facilitate the Discovery and Characterization of Cancer-Specific T-Cell Receptors
ImmunoScape, a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR-T-cell therapeutics announced that it has raised $14M in new financing.
Excision BioTherapeutics Doses First Participant in EBT-101 Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
Excision BioTherapeutics announced that the first participant has been dosed in the Phase 1/2 clinical trial of EBT-101 for human immunodeficiency virus type 1 (HIV-1).
Xendee Releases New Features for Effectively Designing Sustainable Communities, Large Facilities, and Utility-Scale Microgrids
Xendee’s optimization software even takes into account cable length, losses through transferring energy, and the most efficient ways to generate and distribute energy from multiple energy sources at all hours of the day.
ImmunoScape announced that Dan MacLeod, Ph.D., the company’s vice president of discovery, will present at the 7th Annual CAR-TCR Summit taking place September 19-22, 2022 in Boston.
Liquid Instruments Raises $28.5 Million to Revolutionize Technology Development with Software-Defined Test Instrumentation
Growth investment accelerates product innovation, talent acquisition and expansion in commercial, educational markets
Excision BioTherapeutics Inc. announced that Excision Management will present at the following upcoming investor conferences.